Form 4: Crinetics Pharmaceuticals CEO Richard Struthers Reports Gift of Common Stock
SEC Filing Form 4
Richard Scott Struthers, CEO of Crinetics Pharmaceuticals, reported a gift of 350 shares of common stock in a recent SEC filing.
Summary
- On April 18, 2024, Richard Scott Struthers, the President and CEO of Crinetics Pharmaceuticals, reported a transaction involving the company's common stock.
- Struthers gifted 350 shares of common stock.
- Following the transaction, Struthers directly owns 257,485 shares.
- Struthers also indirectly owns shares through family trusts: 570,805 shares through Family Trust 1, and 110,000 shares each through Family Trusts 2, 3, and 4.
- Additionally, Struthers indirectly owns 1,000 shares through his spouse.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a gift transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.
Stakeholder Impact
- The transaction itself is unlikely to have a significant impact on stakeholders.
- However, transparency in insider transactions is important for maintaining investor confidence.
Key Dates
| Date | Description |
|---|---|
| 04/18/2024 | Date of the gift transaction of common stock. |
| 04/22/2024 | Date of signature on the report by Marc Wilson, as attorney-in-fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.